Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 69, No 3 (2018)
Original paper
Submitted: 2017-07-31
Accepted: 2018-02-01
Published online: 2018-03-02
View PDF Download PDF file
Get Citation

Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival

Kosma Woliński1, Rafał Czepczyński1, Adam Stangierski1, Maciej Trojanowski2, Magdalena Rewaj-Łosyk1, Katarzyna Ziemnicka1, Maciej Bączyk1, Agnieszka Dyzmann-Sroka1, Marek Ruchała1
DOI: 10.5603/EP.a2018.0017
·
Pubmed: 29504625
·
Endokrynol Pol 2018;69(3):230-234.
Affiliations
  1. Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Epidemiology and Cancer Prevention , Greater Poland Cancer Centre

open access

Vol 69, No 3 (2018)
Original Paper
Submitted: 2017-07-31
Accepted: 2018-02-01
Published online: 2018-03-02

Abstract

Introduction: Due to a limited number of hospital beds dedicated to radioiodine therapy (RIT) in some countries, a fractionated dose of radioiodine may be considered as the ablation therapy of differentiated thyroid cancer (DTC). The aim of the study was to compare the late effects of ablation therapy with single and fractionated dose of radioiodine in patients with DTC. Patients and methods: Patients with low-risk DTC referred to our institution 5–16 weeks after thyroidectomy, treated with 2.2 GBq of 131I, either in a single dose (2.2 GBq, group 1) or in two fractions (1.1 GBq+1.1 GBq administered with a 24 h interval, group 2) were retrospectively included. Clinical outcome of the treatment and overall survival (OS) was evaluated. Results: 83 patients treated with single dose and 186 patients treated with fractionated dose of radioiodine were included. Mean duration of follow-up was 8.0 vs.7.8 years, respectively (p=ns). There were no significant differences between the groups in male to female ratio, age at the time of the first RIT, proportion of papillary thyroid cancers, volume of the thyroid tissue, thyroid-stimulating hormone and thyroglobulin levels before first RIT. RIT was repeated in 55.4% and 54.8% of patients from group 1 and 2 respectively (p=ns). There were no significant differences including the course and outcomes of the treatment between the groups, measured by: cumulative dose of 131I, mean number of 131I administrations and mean thyreoglobulin concentration at the follow-up. Also the overall survival did not differ significantly between the groups. Probability of 5-year OS was 98.6% for patients treated with single and 99.5% with fractionated dose of 131-I, 10 year OS – 98.6 and 97.1% respectively, 15 year OS – 95.5 and 92.9% respectively (p=ns). Conclusions: In the long-term follow-up, radioiodine ablation therapy with fractionated doses in low-risk DTC patients is equally effective as with single dose.

< p > < /p >

Abstract

Introduction: Due to a limited number of hospital beds dedicated to radioiodine therapy (RIT) in some countries, a fractionated dose of radioiodine may be considered as the ablation therapy of differentiated thyroid cancer (DTC). The aim of the study was to compare the late effects of ablation therapy with single and fractionated dose of radioiodine in patients with DTC. Patients and methods: Patients with low-risk DTC referred to our institution 5–16 weeks after thyroidectomy, treated with 2.2 GBq of 131I, either in a single dose (2.2 GBq, group 1) or in two fractions (1.1 GBq+1.1 GBq administered with a 24 h interval, group 2) were retrospectively included. Clinical outcome of the treatment and overall survival (OS) was evaluated. Results: 83 patients treated with single dose and 186 patients treated with fractionated dose of radioiodine were included. Mean duration of follow-up was 8.0 vs.7.8 years, respectively (p=ns). There were no significant differences between the groups in male to female ratio, age at the time of the first RIT, proportion of papillary thyroid cancers, volume of the thyroid tissue, thyroid-stimulating hormone and thyroglobulin levels before first RIT. RIT was repeated in 55.4% and 54.8% of patients from group 1 and 2 respectively (p=ns). There were no significant differences including the course and outcomes of the treatment between the groups, measured by: cumulative dose of 131I, mean number of 131I administrations and mean thyreoglobulin concentration at the follow-up. Also the overall survival did not differ significantly between the groups. Probability of 5-year OS was 98.6% for patients treated with single and 99.5% with fractionated dose of 131-I, 10 year OS – 98.6 and 97.1% respectively, 15 year OS – 95.5 and 92.9% respectively (p=ns). Conclusions: In the long-term follow-up, radioiodine ablation therapy with fractionated doses in low-risk DTC patients is equally effective as with single dose.

< p > < /p >

Full Text:

View PDF Download PDF file
Get Citation

Keywords

thyroid cancer, differentiated thyroid cancer, radioiodine, fractionated dose, survival

About this article
Title

Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Article type

Original paper

Pages

230-234

Published online

2018-03-02

Page views

2486

Article views/downloads

1334

DOI

10.5603/EP.a2018.0017

Pubmed

29504625

Bibliographic record

Endokrynol Pol 2018;69(3):230-234.

Keywords

thyroid cancer
differentiated thyroid cancer
radioiodine
fractionated dose
survival

Authors

Kosma Woliński
Rafał Czepczyński
Adam Stangierski
Maciej Trojanowski
Magdalena Rewaj-Łosyk
Katarzyna Ziemnicka
Maciej Bączyk
Agnieszka Dyzmann-Sroka
Marek Ruchała

References (14)
  1. Cheng W, Ma C, Fu H, et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab. 2013; 98(4): 1353–1360.
    CrossRefPubMed
  2. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994; 78(3): 629–634.
    CrossRefPubMed
  3. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992; 75(3): 714–720.
    CrossRefPubMed
  4. Czepczyński R, Ziemnicka K, Baczyk M, et al. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Thyroid. 2005; 15(11): 1261–1265.
    CrossRefPubMed
  5. Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009; 94(11): 4171–4179.
    CrossRefPubMed
  6. Haugen B, Alexander E, Bible K, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
    CrossRefPubMed
  7. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Diagnostics and Treatment of Thyroid Carcinoma. Endokrynol Pol. 2016; 67(1): 74–107.
    CrossRefPubMed
  8. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996; 156(19): 2165–2172.
    PubMed
  9. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001; 86(8): 3507–3511.
    CrossRefPubMed
  10. Filesi M, Colandrea M, Montesano T, et al. Thyroid stunning in clinical practice: is it a real problem? Minerva Endocrinol. 2009; 34(1): 29–36.
    PubMed
  11. Yap BK, Murby B. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect. J Clin Endocrinol Metab. 2014; 99(7): 2433–2440.
    CrossRefPubMed
  12. Amin A, Amin M, Badwey A. Stunning phenomenon after a radioactive iodine- ¹³¹I diagnostic whole-body scan: Is it really a point of clinical consideration? Nucl Med Commun. 2013; 34(8): 771–776.
    CrossRefPubMed
  13. Arad E, Flannery K, Wilson GA, et al. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med. 1990; 15(10): 676–677.
    PubMed
  14. Wang SJ, Liu TJ. Use of fractionated doses of iodine-131 for ablation of thyroid remnants. Zhonghua Yi Xue Za Zhi (Taipei). 2002; 65(7): 336–340.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl